Patent Application
20140180077
The invention relates to catheters having expandable members, e.g., balloons, for delivering energy to tissues, i.e., to treat the tissues. The invention also describes methods for monitoring and controlling an amount of energy delivered to the tissue.
Physicians use catheters to gain access to and repair interior tissues of the body, particularly within the lumens of the body such as blood vessels. For example, balloon angioplasty and other catheters often are used to open arteries that have been narrowed due to atherosclerotic disease. Catheters can also be used to deliver devices, e.g., stents or valves to the vasculature. Another common catheter use is to deliver therapy to a tissue, such as a drug, heat, or other forms of energy.
The process of heating a tissue to treat a disorder is generally known as “ablation,” even when the tissue is not removed. When ablation techniques were first pioneered, they were truly ablative, in that layers of tissue were burned away with high temperature tools. It has since been discovered that many disorders can be treated by merely heating, but not necessarily removing the tissue, because the heating causes changes to the tissue, e.g., scarring, or destroys/diminishes vasculature or nerves underlying the tissue. For example, endometrial ablation is commonly used to control uterine bleeding. Endometrial ablation involves heating the tissue of the uterine lining to cause the tissue to scar and to dilate the underlying vasculature.
A newer ablation procedure, known as renal denervation (RDN), uses ablative techniques to damage nerves in the walls of the renal arteries. Damage to the nerves in this area affects sympathetic drive, a part of the autonomic nervous system that controls certain body functions when the body is exposed to stress. In particular, destruction of the nerves adjacent to the renal artery results in lower blood pressure, partially because the mechanism by which blood pressure is elevated due to stress is muted. Where approved, the procedure can be used to treat patients that do not respond sufficiently to hypertension medication. Early clinical trials have shown that patients undergoing this procedure commonly experience a sustained decrease in systolic blood pressure of 25-32 mmHg, and a sustained decrease in diastolic pressure of 12-18 mmHg. See “Symplicity™ RDN System Clinical Trial Data,” at http://www.medtronicrdn.com/intl/healthcare-professionals/symplicity-rdn-system/symplicity-clinical-trial-data/index.htm.
Accordingly, there is a need for advanced ablation devices for performing procedures such as renal denervation.
The invention provides methods and devices for heating an inflation fluid in an ablation balloon catheter in order to improve the accuracy of sensors in the balloon. For example, in order to reduce measurement errors, an ablation balloon is filled with an inflation fluid having substantially the same temperature as the target tissue treatment temperature. Because the inflation fluid is heated, the sensors contacting the tissue experience less convective cooling, and the accuracy of tissue temperature measurement is improved. Thus, using the methods and devices of the invention, a surgeon can be assured that the treated tissues were not overheated, but were raised to a temperature sufficient to affect the desired outcome. The treatment methods of the invention are broadly applicable to any ablative procedure, i.e., wherein energy (e.g., heat) is provided to a tissue to affect a therapeutic change.
Additionally, as described in detail below, the invention includes an expandable balloon having a first temperature sensor integrated into a balloon wall and a second temperature sensor at the distal end of the catheter, typically located away from the balloon wall. The two temperature sensors allow independent measurements of the temperature of the tissue being treated and the temperature of a heated fluid, respectively. The disclosed design increases the accuracy of the tissue temperature measurement made by the first temperature sensor, and results in better outcomes for ablative procedures. In some embodiments, the catheter additionally includes a heating element configured to heat the fluid within the balloon.
Using the disclosed ablation balloon and methods for applying energy to a subject, it will be safer to ablate tissues, and it will be easier to verify that the tissues have been properly heated to achieve the desired results.
The invention provides improved balloon catheters and methods of using the catheters, as well as other expandable devices, to deliver energy to tissues in need of treatment. In particular, the catheters of the invention allow active monitoring of tissue temperatures to reduce the rate of errors in delivering ablative treatment. Because the catheters of the invention use heated fluids in the balloon, there is less error in the temperature measurements due to convective heat loss. While the description focuses primarily on renal artery ablation for renal denervation (RDN) the devices and methods are broadly applicable to other ablative procedures, such as endometrial ablation or resculpting of atherosclerotic vessels, among others.
Ablation procedures typically involve contacting a tissue with a hot tool, such as a catheter, or fluid. The heating process often kills the outermost layer of cells contacting the object, and may damage or modify layers of cells below the outermost layer. Some ablation procedures use directed energy to heat and modify the outermost layer of cells, or a nearby layer of cells (treatment depth). In some embodiments, lasers, microwaves, or radiofrequency (RF) waves are directed at the tissue, causing the tissue to heat to treatment temperatures. Typically, the energy is absorbed directly, thus causing the tissue to heat. In some embodiments, a secondary structure, e.g., an antenna, receives the directed energy and heats the tissues. During a procedure the temperature of the tissue is typically elevated to 50° C. or greater, e.g., 55° C. or greater, e.g., 60° C. or greater, e.g., 65° C. or greater, e.g., 70° C. or greater. In some embodiments the tissue is heated to about 65° C., e.g., 68° C.
In order to minimize risks when performing ablative procedures such as renal denervation (RDN), it is important to monitor and control the temperature of the device and the surrounding tissues. For example, during RDN, the renal artery could be weakened, increasing the chance of embolism, or the renal artery could be perforated or severed. To avoid such damage, prior art devices rely on gated energy delivery to control the temperature of the tissue. That is, RDN devices are programmed to provide predetermined dosing times and wattage based upon accumulated experience and animal/cadaver studies. For example, 4 Watts of radiofrequency energy delivered for 2 seconds has been found to increase the temperature of a cadaver aorta to 65° C. with a particular balloon ablation device. See U.S. Patent Publication No. 2012/0158101 incorporated by reference herein in its entirety. Operation within the suggested range is assumed to provide safe and effective treatment. Nonetheless, without active temperature monitoring, it is impossible to know if the renal artery tissue is overheating. It is also difficult to assure that the target tissue was, in fact, raised to a temperature suitable to denerve the tissue. Using prior art methods, it is impossible to determine if the tissue has been adequately denerved without prolonged blood pressure monitoring after the procedure.
In order to address these concerns, the invention places an expandable member (e.g., a balloon) having a temperature sensor in proximity to the tissues (e.g., blood vessels), and expands the expandable member to cause the expandable member to contact the tissue and deliver therapy. For example, a heated fluid, having a temperature similar to a target therapy temperature, can be provided to the expandable member to increase the accuracy of tissue temperature measurements. During the ablative procedure, i.e., while energy is applied to the tissue via the expandable member, the tissue temperature is measured with a sensor in the presence of the heated fluid. Based upon the temperature assessments, the treatment is continued until the tissue has reached a target therapeutic temperature. Because the temperature measurement is more accurate than current methods, it is less likely that the tissue will be overheated, and it is more likely that the tissue will reach the target temperature during the procedure.
Housing 29 also accommodates an electrical connector 38. Connector 38 includes a plurality of electrical connections, each electrically coupled to electrodes 34 via conductors (not shown). Electrodes 34 are energized and controlled by a controller 40 and power source 42, such as bipolar or monopolar RF energy, microwave energy, ultrasound energy, voltage source, current source, or other suitable energy source. In an embodiment, electrical connector 38 is coupled to an RF generator via a controller 40, with controller 40 allowing energy to be selectively directed to electrodes 34. When monopolar RF energy is employed, the patient may be grounded by connecting an external electrode, or an electrode connected to the catheter body 14, to the patient.
The controller 40 includes a processor, or is coupled to a processor, to control and/or record treatment. The processor will typically comprise computer hardware and/or software, often including one or more programmable processor units running machine readable program instructions or code for implementing some or all of one or more of the methods described herein. The code will often be embodied in a tangible media such as a memory (optionally a read only memory, a random access memory, a non-volatile memory, or the like) and/or a recording media (such as a floppy disk, a hard drive, a CD, a DVD, a non-volatile solid-state memory card, or the like). The code and/or associated data and signals may also be transmitted to or from the processor via a network connection, and some or all of the code may also be transmitted between components of catheter system 10 and within processor 40.
The balloon 20 generally includes a proximal portion coupled to an inflation lumen and a distal portion coupled to a guide wire lumen. (See
Catheter bodies intended for intravascular introduction will typically have a length in the range from 50 cm to 200 cm and an outer diameter in the range from 1 French to 12 French (0.33 mm: 1 French), usually from 3 French to 9 French. In the case of fistula treatment catheters, the length is typically in the range from 60 cm to 150 cm, the diameter is preferably below 8 French, more preferably below 7 French, and most preferably in the range from 2 French to 7 French.
Catheter bodies will typically be composed of a biocompatible polymer that is fabricated by conventional extrusion techniques. Suitable polymers include polyvinylchloride, polyurethanes, polyesters, polytetrafluoroethylenes (PTFE), silicone rubbers, natural rubbers, and the like. Optionally, the catheter body may be reinforced with braid, helical wires, coils, axial filaments, or the like, in order to increase rotational strength, column strength, toughness, pushability, and the like. Suitable catheter bodies may be formed by extrusion, with one or more channels being provided when desired. The catheter diameter can be modified by heat expansion and shrinkage using conventional techniques. The resulting catheters will thus be suitable for introduction to the vascular system, often the coronary arteries, by conventional techniques.
In an embodiment, the balloon 20 is configured with electrodes 34 integrated into the wall of the balloon 20 to deliver RF energy to heat tissues. The electrodes 34 may be mounted on an inside surface of balloon 20, with associated connectors/wires extending proximally from the electrodes. The electrodes 34 may be sandwiched between layers of balloon material. The electrodes 34 may be arranged in any suitable pattern, such as stripes, helixes, saw tooth, rings, or arrays.
The system may be used for monopolar or bipolar application of energy. For delivery of monopolar energy, a ground electrode is used, either on the catheter shaft, or on the patient's skin, such as a ground electrode pad. For delivery of bipolar energy, adjacent electrodes are axially offset to allow bipolar energy to be directed between adjacent circumferential (axially offset) electrodes. In other embodiments, electrodes may be arranged in bands around the balloon to allow bipolar energy to be directed between adjacent distal and proximal electrodes.
In another embodiment, the system heats tissues using heated fluids. In this configuration, balloon 20 need not include electrodes 34. In this embodiment, the balloon is substantially impervious to aqueous solutions, e.g., saline, to prevent the heated fluid from leaving the balloon. In an embodiment, the catheter includes an insulated lumen for delivering heated fluids to the balloon, e.g., heated saline. The fluid may have a temperature of 37° C. or greater, e.g., 40° C. or greater, e.g., 45° C. or greater, e.g., 50° C. or greater, e.g., 55° C. or greater, e.g., 60° C. or greater, e.g., 65° C. or greater, e.g., about 68° C. Systems of the catheter 10, configured to heat tissues with heated fluids may comprise a heated fluid reservoir and a pump connected to the inflation lumen to deliver the heated fluids (not shown). Other embodiments for heating tissues with heated fluids may comprise a heating element inside of the balloon as an element of the catheter. The balloon may be filled with room or body temperature saline directed to the balloon via an inflation lumen, and then the fluid can be heated with the heating element to provide a heated fluid. In some embodiments, a balloon catheter will also include a temperature sensor located proximate to the center of the balloon to be used to measure the temperature of the heated fluid.
In an embodiment, the balloon 20 is configured with temperature sensors integrated into the wall of the balloon. The temperature sensors may be mounted on an inside surface of balloon 20, with associated connectors/wires extending proximally from the temperature sensors. The temperature sensors may be mounted on an inside surface of the balloon 20. The temperature sensors may be sandwiched between layers of balloon material. The temperature sensors may be arranged in any suitable pattern, such as an array. The temperature sensors may be any temperature sensor that has a sufficiently small profile to be incorporated into the balloon, for example the temperature sensors may be a thermocouple, thermistor, thermal diode, or other suitable device. In some embodiments, the catheter will comprise an additional heating element that is inside the balloon, e.g., in proximity to a distal end of the inflation lumen, thereby allowing the inflation fluid, e.g., a heated inflation fluid, to be monitored.
A generalized depiction of an ablation process is shown in
Regarding
Once the balloon 20 has engaged the vessel wall tissues, the electrodes 34 will be energized to treat the tissue. As shown in
Catheters of the invention are described in greater detail in
Once the expandable member 310 is expanded and filled with a heated fluid, the heating elements 320 will be energized to deliver energy to the tissue 380. Depending upon the procedure, the energy delivered to the tissue 380 will ablate the tissue 380 or affect a change to tissues/structures nearby the tissue 380 such as a nerve 390. Thus, in a renal denervation procedure, the nerve 390 will be disabled by the delivered energy. While the energy is delivered via heating elements 320, the temperature sensors 330 will monitor the temperature of the tissue to assure that the tissue does not exceed a safe temperature. The temperature sensors 330 will also monitor the temperature of the tissue to assure that it reaches the temperature needed for treatment.
In some embodiments, the optimum temperature to achieve renal denervation is 68° C. In this embodiment, the inner volume 350 is filled with a heated fluid also having a temperature of 68° C. As discussed previously, the heated fluid can be provided externally, e.g., through an insulated lumen, or the fluid can be heated once inside the expanding member, e.g., with heating element 420. Because the catheters are filled with a heated fluid that matches the desired tissue temperature, the heated solution cannot act as a heat sink against the heating elements 320, as is the case with current ablation catheters. Thus, the temperature sensors 330 will not sense a temperature that is lower than the actual temperature of the tissue, thereby assuring that the tissue is not overheated and damaged. Additionally, the heated fluid will help to provide even heating to the tissue to assure that the desired tissues do reach the desired temperatures.
When using an expandable member 310 configured as described above, it will not be necessary to gate the energy delivery during treatment. Rather, it will be a simple matter of comparing the temperature measured with the temperature sensor 330 to a predetermined temperature, e.g., 68° C. This method is shown in greater detail in
Advanced embodiments of the methods may include algorithms for monitoring or measuring the treatment area temperature. For example, readings from multiple temperature sensors 330 at different points on expandable member 330 may be modeled to develop a heat map of how the tissue is heating. Additionally, if the heating elements are individually addressable, it may be possible to turn some off and leave others on in order to achieve more even heating. Other algorithms may be used to estimate overshoot to determine if and when the heating elements should be turned off prior to Tm exceeding Tc.
In some embodiments, a catheter of the invention will additionally include imaging capabilities, such as intravascular ultrasound (IVUS) imaging or optical coherence tomography (OCT). The IVUS imaging assembly may be phased array IVUS imaging assembly, an pull-back type IVUS imaging assembly, or an IVUS imaging assembly that uses photoacoustic materials to produce diagnostic ultrasound and/or receive reflected ultrasound for diagnostics. IVUS imaging assemblies and processing of IVUS data are described for example in Yock, U.S. Pat. Nos. 4,794,931, 5,000,185, and 5,313,949; Sieben et al., U.S. Pat. Nos. 5,243,988, and 5,353,798; Crowley et al., U.S. Pat. No. 4,951,677; Pomeranz, U.S. Pat. No. 5,095,911, Griffith et al., U.S. Pat. No. 4,841,977, Maroney et al., U.S. Pat. No. 5,373,849, Born et al., U.S. Pat. No. 5,176,141, Lancee et al., U.S. Pat. No. 5,240,003, Lancee et al., U.S. Pat. No. 5,375,602, Gardineer et at., U.S. Pat. No. 5,373,845, Seward et al., Mayo Clinic Proceedings 71(7):629-635 (1996), Packer et al., Cardiostim Conference 833 (1994), “Ultrasound Cardioscopy,” Eur. J.C.P.E. 4(2):193 (June 1994), Eberle et al., U.S. Pat. No. 5,453,575, Eberle et al., U.S. Pat. No. 5,368,037, Eberle et at., U.S. Pat. No. 5,183,048, Eberle et al., U.S. Pat. No. 5,167,233, Eberle et at., U.S. Pat. No. 4,917,097, Eberle et at., U.S. Pat. No. 5,135,486, and other references well known in the art relating to intraluminal ultrasound devices and modalities. All of these references are incorporated by reference herein.
In other embodiments, the imaging may use optical coherence tomography (OCT). OCT is a medical imaging methodology using a miniaturized near infrared light-emitting probe, and is capable of acquiring micrometer-resolution, three-dimensional images from within optical scattering media (e.g., biological tissue). OCT systems and methods are generally described in Castella et al., U.S. Pat. No. 8,108,030, Milner et al., U.S. Patent Application Publication No. 2011/0152771, Condit et al., U.S. Patent Application Publication No. 2010/0220334, Castella et al., U.S. Patent Application Publication No. 2009/0043191, Milner et al., U.S. Patent Application Publication No. 2008/0291463, and Kemp, N., U.S. Patent Application Publication No. 2008/0180683, the content of each of which is incorporated by reference in its entirety.
Other embodiments of catheters and methods of using them, not disclosed herein, will be evident to those of skill in the art, and are intended to be covered by the claims listed below.
References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
This application claims priority to U.S. Provisional Application No. 61/745,248, filed Dec. 21, 2012, which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61745248 | Dec 2012 | US |
